SenzaGen SEK 30m Directed Issue | Q4 2021

About SenzaGen

SenzaGen aims to be a leader in non-animal toxicology testing driving the transition from animal testing to methods better suited to reflect human biology. The company has a growth strategy which involve continued commercialization of the in house developed GARD® test platform, expansion of the test portfolio with a broader range of tests and pursuing acquisition opportunities of profitable and growing companies with complementary offerings. The company´s state-of-the-art GARD® test platform combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract. Its high informational content and a holistic view of the immunological responses contribute to high predictive accuracy and human relevance. SenzaGen has its headquarters and GLP certified laboratory in Lund, Sweden, and a subsidiary in the US.

Press release

The case

• Targeting category leadership within non-animal testing through continued execution upon the accelerated growth strategy involving acquisitions and rapid organic growth.


• Genomics, machine learning and biology is combined in the company’s GARD®-platform, resulting in accuracy of over 90%, ability to handle challenging samples in small quantities and with short turn-around time.


• The positive EURL ECVAM evaluation of GARD®skin significantly increases OECD’s likelihood of final approval, enabling SenzaGen to offer the GARD® technology to a significantly broader customer base, further expanding the market potential.

SenzaGen website